Sartorius AG Reports 7.5% Sales Growth and Higher Earnings for First Nine Months of 2025
Sartorius AG reported a 7.5% sales growth for the first nine months of 2025, with group sales revenue reaching €2.92 billion. The Bioprocess Solutions division grew by approximately 10%, while the Lab Products & Services division showed recovery. EBIT increased to €399.0 million, and net profit rose to €186.4 million. The operating earnings margin improved to 29.7%. However, cash flow from financing activities decreased significantly, and cash and cash equivalents fell to €389.9 million.
Sartorius AG reported sales growth of 7.5% for the first nine months of 2025. Group sales revenue reached €2.92 billion, up from €2.72 billion in the same period in 2024. The Bioprocess Solutions division recorded an increase of approximately 10%, while the Lab Products & Services division showed signs of recovery. Earnings before interest and tax (EBIT) rose to €399.0 million, compared to €297.2 million in the first nine months of 2024. The company’s net profit for the period was €186.4 million, up from €114.7 million a year earlier. The operating earnings margin improved by two percentage points to 29.7%. Cash flow from financing activities decreased to minus €552.8 million, compared to minus €82.5 million in the prior-year period. Cash and cash equivalents at the end of the period were €389.9 million, down from €579.2 million at the end of the first nine months of 2024. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sartorius AG published the original content used to generate this news brief on October 15, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
